10,500 Shares in Guardant Health, Inc. (NASDAQ:GH) Purchased by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) during the 2nd quarter, HoldingsChannel.com reports. The fund acquired 10,500 shares of the company’s stock, valued at approximately $303,000.

A number of other large investors also recently bought and sold shares of the stock. Canton Hathaway LLC acquired a new stake in shares of Guardant Health during the second quarter valued at about $59,000. Byrne Asset Management LLC purchased a new position in shares of Guardant Health during the 2nd quarter worth approximately $77,000. Manchester Capital Management LLC acquired a new stake in Guardant Health in the 1st quarter valued at approximately $57,000. EntryPoint Capital LLC acquired a new stake in Guardant Health in the 1st quarter valued at approximately $75,000. Finally, Fullcircle Wealth LLC purchased a new stake in Guardant Health in the second quarter valued at approximately $211,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Trading Up 0.7 %

Shares of NASDAQ:GH opened at $22.88 on Friday. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $37.04. The company’s 50 day moving average is $27.92 and its two-hundred day moving average is $25.18. The company has a market cap of $2.80 billion, a PE ratio of -5.84 and a beta of 1.11. The company has a current ratio of 6.40, a quick ratio of 6.07 and a debt-to-equity ratio of 16.70.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.10). The business had revenue of $177.24 million during the quarter, compared to analyst estimates of $162.59 million. Guardant Health had a negative net margin of 76.23% and a negative return on equity of 418.21%. The firm’s quarterly revenue was up 29.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.67) earnings per share. Equities analysts predict that Guardant Health, Inc. will post -3.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

GH has been the subject of several research analyst reports. Jefferies Financial Group assumed coverage on Guardant Health in a research report on Monday, June 3rd. They set a “buy” rating and a $32.00 price target for the company. Craig Hallum raised their target price on Guardant Health from $28.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, August 8th. The Goldman Sachs Group boosted their price target on shares of Guardant Health from $28.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, July 17th. JPMorgan Chase & Co. increased their price target on shares of Guardant Health from $45.00 to $48.00 and gave the stock an “overweight” rating in a research report on Thursday, August 8th. Finally, TD Cowen lifted their price objective on shares of Guardant Health from $41.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $39.67.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.